Top of this page
Skip navigation, go straight to the content Newsroom Newsroom


Spotlight Story

UCB's Committment to Neurology

We recently announced an exciting addition to UCB’s epilepsy pipeline with an agreement to acquire the rights to Proximagen’s Midazolam Nasal Spray (USL261),an anti-epilepsy drug (AED) developed as an intended rescue treatment for acute repetitive seizures (ARS, also known as serial, recurrent or cluster seizures) in patients with epilepsy.

Read More


1  USL261 has not been submitted to or approved by the FDA. These statements solely reflect the opinions of the authors.


UCB U.S. News

 Apr 25, 2018

UCB’s Dr. Victor Sloan Shares His Commitment to Go Boldly

Read more
Apr 20, 2018

UCB’s Commitment in Neurology

Read more
Apr 20, 2018

Press Release: UCB to expand epilepsy portfolio with strategic acquisition …

Read more